Plotnikov A N, Staroverov I I, Tagieva I A, Dorogun B N, Pomerantsev E V, Dobrovol'skiĭ A B, Ruda M Ia
Kardiologiia. 1993;33(3):32-6.
Search for more effective and safe drugs has recently led to the design of second-generation thrombolytic enzymes one of which is recombinant tissue plasminogen activator. A total of 80 patients including 41 who received tissue plasminogen activator (TPA) (Group 1), 39 on streptokinase (SK) (Group 2) were examined. By the 90th minute of thrombolytic infusion, coronary blood flow was recovered in 27 (66%) patients from Group 1 and 19 (49%) from Group 2 (p = 0.12). A decrease in fibrinogen concentration by less than 1 g/l was seen in 7 (18.4%) patients from Group 1 and in 29 (82.9%) patients from Group 2 (p = 0.00005). The levels of fibrinogen and plasminogen during 36 hours of initiation of thrombolytic infusion were statistically significantly lower in Group 2. The incidence of hemorrhages was the same in the two groups and equal to 26.8 and 28.0% in Groups 1 and 2, respectively. All the patients had no hemorrhages requiring transfusion of blood and its substitutes, as well as no cerebral circulatory disorders in the first week of the disease.
近期，对更有效且安全药物的探寻促使了第二代溶栓酶的设计，其中之一便是重组组织型纤溶酶原激活剂。总共检查了80名患者，其中41名接受了组织型纤溶酶原激活剂（TPA）治疗（第1组），39名接受了链激酶（SK）治疗（第2组）。到溶栓输注第90分钟时，第1组27名（66%）患者的冠状动脉血流恢复，第2组19名（49%）患者的冠状动脉血流恢复（p = 0.12）。第1组7名（18.4%）患者和第2组29名（82.9%）患者的纤维蛋白原浓度下降小于1 g/l（p = 0.00005）。溶栓输注开始后36小时内，第2组的纤维蛋白原和纤溶酶原水平在统计学上显著更低。两组的出血发生率相同，第1组和第2组分别为26.8%和28.0%。所有患者在疾病的第一周均未出现需要输血及其替代品的出血情况，也未出现脑循环障碍。
